News & Updates
Showing Multidisciplinary articles
Showing
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
Treatment with sodium-glucose cotransporter 2 inhibitors (SGLT2i) leads to lower rates of cardiovascular disease (CVD) events in patients with type 2 diabetes mellitus (T2DM) than does dipeptidyl peptidase-4 inhibitors (DPP4i), reports a recent Japan study.
SGLT2i beats DPP4i at reducing cardiovascular disease in type 2 diabetes
18 May 2022
High BMI might promote MGUS progression to multiple myeloma
In individuals with monoclonal gammopathy of undetermined significance (MGUS), obesity or high body mass index (BMI) seems to aggravate the risk of disease progression to multiple myeloma (MM), an effect that appears to be stronger in women, a recent study has found.
High BMI might promote MGUS progression to multiple myeloma
17 May 2022
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
Combination therapy with relugolix (once daily relugolix 40 mg, estradiol 1 mg, norethindrone acetate 0.5 mg) leads to improvement in heavy menstrual bleeding (HMB) and in other uterine fibroid (UF)-related symptoms independent of the location of the largest fibroid, results of a recent study have shown.
Relugolix combo improves uterine fibroid symptoms regardless of fibroid location
17 May 2022
Adults with nephrotic syndrome at greater risk of thromboembolism, bleeding
The risk of arterial thromboembolism, venous thromboembolism, and bleeding is higher in adults with nephrotic syndrome than the general population, a study has found. However, the mechanisms and consequences of this association warrant further research.